AUS
NZ
UK
CA
USA
IND
Highlights
Hikma Pharmaceuticals disclosed a share transaction by a board member
Non-Executive Director Laura Balan purchased ordinary shares of the company
Transaction took place on the London Stock Exchange on twenty second August
Hikma Pharmaceuticals PLC operates within the healthcare and pharmaceuticals sector, with a focus on providing branded and generic medicines across multiple markets. The company is listed on the London Stock Exchange under the ticker (LSE:HIK) and is a constituent of the FTSE 350 today. The organisation maintains a presence in both established and emerging markets, offering products in areas such as injectables, branded formulations, and generic oral medicines.
Notification of Transaction
The company announced a transaction involving a person discharging managerial responsibilities in accordance with Article nineteen of the EU Market Abuse Regulation, as retained in UK law. This type of disclosure ensures transparency and compliance with regulatory obligations. The company provided full details in line with Article nineteen paragraph three of the regulation, making the information available to the market.
Details of the Individual
The individual associated with the disclosed transaction is Laura Balan, who serves as a Non-Executive Director on the board of Hikma Pharmaceuticals. The filing confirmed that this notification represents an initial disclosure under the requirements.
Issuer Information
The issuer of the shares is Hikma Pharmaceuticals PLC, registered under the Legal Entity Identifier code 549300BNS685UXH4JI75. The company continues to operate as a significant participant in the pharmaceutical industry with listings on both the London Stock Exchange and Nasdaq Dubai.
Nature of the Transaction
The transaction involved the purchase of ordinary shares with a nominal value of ten pence each. These shares carry the identification code GB00B0LCW083. The disclosure confirmed that the activity was a straightforward purchase of shares in the company.
Price and Volume
The filing recorded the acquisition at a price of eighteen pounds and twenty pence per share, with a total of three thousand five hundred shares purchased. The aggregated value of the transaction amounted to just under sixty four thousand pounds.
Date and Venue
The transaction took place on the twenty second of August in the year twenty twenty five. The venue of the transaction was the London Stock Exchange, denoted by the code XLON.
Regulatory Compliance
This disclosure aligns with the obligations placed on issuers and persons discharging managerial responsibilities under the European Union Market Abuse Regulation. By publishing the notification, Hikma Pharmaceuticals upholds its commitment to maintaining transparency within the capital markets. Such announcements provide clarity to the broader market by ensuring that all participants have access to relevant and accurate information regarding board-level transactions.
